Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study.
Yael N KusneTerra LashoChristy FinkeZaid ElsabbaghShaylene McCueTimothy J HobdayJason S StarrTanios S Bekaii-SaabThorvardur R HalfdanarsonMirinal S PatnaikFang-Shu OuMohamad Bassam B SonbolPublished in: JCO precision oncology (2024)
CH is present in 35.1% of patients with NET and is associated with thrombocytopenia risk during PRRT. Future studies with long-term follow-up will delineate whether CH might be a predictor for higher risk of t-MN after PRRT.